Cours suspendu

Communiqués Cyclo Therapeutics, Inc.

Actions

CYTH

US23254X2018

Produits pharmaceutiques

Temps Différé Nasdaq Autres places de cotation 21:00:00 25/03/2025			Varia. 5j.	Varia. 1 janv.
0,7206 ^USD	+1,39%		-.--%	-

22/04	Cyclo Therapeutics conclut un accord de licence exclusive avec le Massachusetts Institute of Technology	CI
27/08/25	Cyclo Therapeutics : deux abstracts retenus pour des présentations orales et par affiche au 15^e Congrès international des erreurs innées du métabolisme	CI

Communiqués

26/03/25	Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals	AQ
20/02/25	CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH	BU
10/02/25	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing phase 3 TransportNPC Open-Label Sub-Study in Patients	AQ
07/02/25	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)	BU
15/01/25	Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium 2025	AQ
14/01/25	Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025	BU
27/11/24	Cyclo Therapeutics : Amendment to Annual Report Form 10 K/A	PU
14/11/24	Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update	BU
07/11/24	Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results	AQ
09/10/24	Cyclo Therapeutics : Failure to Satisfy Listing Rule Form 8 K	PU
05/09/24	Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)	BU
26/08/24	CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH	BU
15/08/24	Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update	BU
29/07/24	Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office	BU
26/06/24	Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024	AQ
25/06/24	Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024	BU
31/05/24	Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	AQ
16/05/24	Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	BU
02/05/24	Cyclo Therapeutics : Corporate Presentation	PU
18/04/24	Cyclo Therapeutics : Corporate Presentation	PU
18/03/24	Cyclo Therapeutics : Corporate Presentation	PU
18/03/24	Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	BU
15/03/24	Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimer's Disease	AQ
14/03/24	Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease	BU
30/01/24	Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office	AQ